Betagistin

General characteristics. Structure:

Active agent: betagistina dihydrochloride of 8 mg; 16 mg; 24 mg.

Excipients: lactoses monohydrate (sugar milk), cellulose microcrystallic, potato starch, коповидон, carboxymethylstarch of sodium, silicon dioxide colloid, magnesium stearate.

Description:
Tablets of color of a ploskotsilindrichesky form, white or white with a cream shade, with a facet from two parties and risky on the one hand.

Pharmacological properties:

Betagistin affects mainly histamine H1 and N3 - receptors of an inner ear and vestibular nuclei of the central nervous system. By direct agonistic impact on H1 receptors of vessels of an inner ear, and also indirectly on H3-histamine receptors vestibular, kernels of the central nervous system (CNS); improves microcirculation and permeability of capillaries, normalizes endolymph pressure in a labyrinth and a snail. At the same time бетагистин increases a blood stream in a basilar artery. Accelerates recovery of vestibular function after a unilateral vestibular neurectomy, accelerating and facilitating the central vestibular compensation (due to antagonism with H3-histamine receptors). Has the expressed central effect, being H3 receptors inhibitor of kernels of a vestibular nerve. Dozozavisimo reduces generation of action potentials in neurons of lateral and medial vestibular nuclei.
Facilitates symptomatology at Menyer's syndrome and vestibular dizziness. The stable therapeutic effect occurs in 14 days.

Pharmacokinetics. Communication with proteins of plasma - low is absorbed quickly. Time of achievement of the maximum concentration in plasma (TCmax) 3 hours. It is metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and demetilbetagistina. 85-90% are removed by kidneys in the form of 2-pyridylacetic acid within 24 hours. Removal of a betagistin and demetilbetagistin kidneys slightly. Intestines remove only a small part of a betagistin and its metabolites.

Indications to use:

- The treatment of a syndrome of Menyer who is characterized by dizziness (which is followed by nausea and vomiting), decrease in hearing and a sonitus.
- Symptomatic treatment of vestibular dizziness (вертиго).

Route of administration and doses:

Inside, during food. Tablets of 8 mg: 1-2 tablets 3 times a day. Tablets of 16 mg: ½-1 a tablet 3 times a day.
Improvement is usually noted already at the beginning of therapy, the stable therapeutic effect occurs after two weeks of treatment and can - increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individually.

Features of use:

The therapeutic effect in some cases increases within several months from an initiation of treatment.

Influence on ability to driving and other mechanisms
Betagistin does not possess sedation and does not influence ability to drive the car or to be engaged in the types of activity demanding speed of psychomotor reactions.

Side effects:

- From the alimentary system: nausea, vomiting, abdominal pain, abdominal distention, dyspepsia.
- From integuments: Quincke's disease, small tortoiseshell, itch, rash.
- Allergic reactions: hypersensitivity, including anaphylactic reactions.

Interaction with other medicines:

Cases of interaction or incompatibility with other medicines are unknown.

Contraindications:

Hypersensitivity to any of drug components, pregnancy and the period of a lactation (due to the lack of data). Children's age. Lactose intolerance, deficit of lactase and syndrome of glyukozo-galaktozny malabsorption.

With care
Peptic ulcer of a stomach or 12-perstny gut (including in the anamnesis), a pheochromocytoma, bronchial asthma. The specified patients should be observed regularly during treatment.

Pregnancies and period of a lactation
There are not enough data for assessment of influence of drug during pregnancy and a lactation. In this regard reception at pregnancy is not recommended. For the period of treatment it is necessary to stop breastfeeding.

Overdose:

Symptoms: nausea, abdominal pain, drowsiness (at reception in a dose to 640 mg); spasms, cardiovascular complications (at reception in a dose more than 640 mg or in combination with other medicines).

Treatment: symptomatic.

Storage conditions:

In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets of 8 mg; 16 mg; 24 MG.
On 10, 30 tablets place in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 10, 20, 30, 40, 50 or 100 tablets place in a container polymeric for medicines. One container or 1, 2, 3, 4, 5, 6, 8 or 10 blister strip packagings together with the application instruction place in a pack from a cardboard.